Terms: = Lung cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Prognosis
928 results:
1. Down-regulation of KLRB1 is associated with increased cell growth, metastasis, poor prognosis, as well as a dysfunctional immune microenvironment in LUAD.
Chen JL; Wu CY; Luo XY; Wang XY; Wang FM; Huang X; Yuan W; Guo Q
Sci Rep; 2024 May; 14(1):11782. PubMed ID: 38782996
[TBL] [Abstract] [Full Text] [Related]
2. Common immunological and prognostic features of lung and bladder cancer via smoking-related genes: PRR11 gene as potential immunotherapeutic target.
Wang Y; Zhu H; Zhang L; He J; Bo J; Wang J; Ding B; Ren M
J Cell Mol Med; 2024 May; 28(10):e18384. PubMed ID: 38760964
[TBL] [Abstract] [Full Text] [Related]
3. Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for metastatic bone tumor resection in patients with PSC.
Bao Z; Yu X; Zheng K; Zhai K; Cui H; Xu M
Front Immunol; 2024; 15():1372279. PubMed ID: 38756778
[TBL] [Abstract] [Full Text] [Related]
4. Implications of GCLC in prognosis and immunity of lung adenocarcinoma and multi-omics regulation mechanisms.
Huang Z; Liang F; Wu J; Huang Z; Li Y; Huang X; Liu Z
BMC Pulm Med; 2024 May; 24(1):239. PubMed ID: 38750474
[TBL] [Abstract] [Full Text] [Related]
5. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
Dang J; Xu G; Guo G; Zhang H; Shang L
J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
[TBL] [Abstract] [Full Text] [Related]
6. Clinical Validation of Artificial Intelligence-Powered pd-l1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non-Small Cell lung cancer.
Kim H; Kim S; Choi S; Park C; Park S; Pereira S; Ma M; Yoo D; Paeng K; Jung W; Park S; Ock CY; Lee SH; Choi YL; Chung JH
JCO Precis Oncol; 2024 May; 8():e2300556. PubMed ID: 38723233
[TBL] [Abstract] [Full Text] [Related]
7. Prediction of Responsiveness to pd-l1/PD-1 Inhibitors Using miRNA Profiles Associated With pd-l1 Expression in lung Adenocarcinoma and Squamous Cell Carcinoma.
Koh YW; Han JH; Haam S; Lee HW
Anticancer Res; 2024 May; 44(5):2081-2089. PubMed ID: 38677736
[TBL] [Abstract] [Full Text] [Related]
8. Identification of the ferroptosis-related prognostic gene signature in mesothelioma.
Wang Z; Huang J; MinYang ; Fu L; Liu S; Huang J; Han J; Zhao X
Gene; 2024 Aug; 919():148498. PubMed ID: 38670397
[TBL] [Abstract] [Full Text] [Related]
9. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
[TBL] [Abstract] [Full Text] [Related]
10. SLC7A11 inhibits ferroptosis and downregulates pd-l1 levels in lung adenocarcinoma.
Huang Z; Chen X; Wang Y; Yuan J; Li J; Hang W; Meng H
Front Immunol; 2024; 15():1372215. PubMed ID: 38655266
[TBL] [Abstract] [Full Text] [Related]
11. Case report: Pathological complete response induced by immunochemotherapy in a case of Pulmonary Sarcomatoid Carcinoma staged IIIA-N2.
Guo Y; Liu X; Tang H; Qiu Z; Ma F; Hu A; Liu C; Wang Y
Front Immunol; 2024; 15():1374270. PubMed ID: 38650938
[TBL] [Abstract] [Full Text] [Related]
12. Analysis of cancer-associated fibroblasts related genes identifies COL11A1 associated with lung adenocarcinoma prognosis.
Zheng H; Tan J; Qin F; Zheng Y; Yang X; Qin X; Liao H
BMC Med Genomics; 2024 Apr; 17(1):97. PubMed ID: 38649961
[TBL] [Abstract] [Full Text] [Related]
13. Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer.
Zheng L; Hu F; Huang L; Lu J; Yang X; Xu J; Wang S; Shen Y; Zhong R; Chu T; Zhang W; Li Y; Zheng X; Han B; Zhong H; Nie W; Zhang X
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38641349
[TBL] [Abstract] [Full Text] [Related]
14. Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy.
Brun SS; Hansen TF; Wen SWC; Nyhus CH; Bertelsen L; Jakobsen A; Hansen TS; Nederby L
Sci Rep; 2024 Apr; 14(1):8993. PubMed ID: 38637655
[TBL] [Abstract] [Full Text] [Related]
15. Effect of the STK11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses.
Xu K; Lu W; Yu A; Wu H; He J
BMC Cancer; 2024 Apr; 24(1):491. PubMed ID: 38632512
[TBL] [Abstract] [Full Text] [Related]
16. The Expression and Prognostic Significance of ICOS in NSCLC Integrated Pan-cancer and Multi-Omics Analyses.
Chen M; Yan X; Hong B; Xiao Y; Qian Y
Int J Med Sci; 2024; 21(5):795-808. PubMed ID: 38616999
[No Abstract] [Full Text] [Related]
17. Predictive Value of NLR and PLR in Driver-Gene-Negative Advanced Non-Small Cell lung cancer Treated with PD-1/pd-l1 Inhibitors: A Single Institutional Cohort Study.
Yuan Q; Xu C; Wang W; Zhang Q
Technol Cancer Res Treat; 2024; 23():15330338241246651. PubMed ID: 38613344
[TBL] [Abstract] [Full Text] [Related]
18. Targeted therapeutic options in early and metastatic NSCLC-overview.
Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z
Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928
[TBL] [Abstract] [Full Text] [Related]
19. [Clinical characteristics and prognosis analysis of pulmonary sarcomatoid carcinoma].
Feng XY; Chen MJ; Xu Y; Zhong W; Liu XY; Gao XX; Zhao J; Wang MZ
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):319-324. PubMed ID: 38599806
[No Abstract] [Full Text] [Related]
20. Purine metabolism in lung adenocarcinoma: A single-cell analysis revealing prognostic and immunotherapeutic insights.
Zhang P; Pei S; Zhou G; Zhang M; Zhang L; Zhang Z
J Cell Mol Med; 2024 Apr; 28(8):e18284. PubMed ID: 38597415
[TBL] [Abstract] [Full Text] [Related]
[Next]